Exhibit 10.2

EMPLOYMENT AGREEMENT

This Employment Agreement (this “Agreement”) is made as of the 10th day of May,
2011, by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation
(the “Corporation”), and Dr. James Bender (hereinafter called “Executive”).

W I T N E S S E T H:

WHEREAS, the Corporation previously employed Executive as its Vice President –
Product Development and Manufacturing under an Employment Agreement dated as of
February 1, 2010 (the “Prior Agreement”);

WHEREAS, the term of the Prior Agreement expired on January 31, 2011; and

WHEREAS, the Corporation desires to continue to employ Executive as its Vice
President – Product Development and Manufacturing under a new employment
pursuant to the terms of this Agreement, and Executive is willing to accept such
employment on the terms and subject to the conditions hereinafter set forth;

NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth,
the parties hereto agree as follows:

1. Employment by Corporation. The Corporation hereby agrees to employ Executive
to continue to perform the duties on behalf of the Corporation as the
Corporation’s full-time Vice President – Product Development and Manufacturing
of the Corporation. As Vice President – Product Development and Manufacturing,
Executive will report to the Corporation’s President and Chief Executive
Officer, and shall have such duties consistent with that of a Vice President –
Product Development and Manufacturing of a company such as the corporation
including without limitation assisting the Corporation in establishing and
implementing plans and strategies for the formulation and development of the
Corporation’s product candidates, securing and monitoring manufacturers for
clinical supplies of product candidates, and assuring that the Company’s
manufacturing activities comply with all applicable FDA requirements. Executive
will perform his duties under this Agreement at the Corporation’s corporate
headquarters in the metropolitan Los Angeles area, with such office currently
located in the Woodland Hills, California area, or at such other location as
shall be mutually agreed upon by the Corporation and Executive; and he will do
such traveling as may be required of him in the performance of his duties.

2. Executive’s Acceptance of Employment. Executive hereby accepts such
employment and agrees that throughout the period of his employment hereunder he
will devote his full time, attention, knowledge and skills, faithfully,
diligently and to the best of his ability, in furtherance of the business of the
Corporation, and he will perform the duties assigned to him pursuant to
Section 1 hereof, subject, at all times, to the direction and control of the
Corporation’s President and Chief Executive Officer.

--------------------------------------------------------------------------------

Executive shall at all times be subject to, observe and carry out such
reasonable rules, regulations, policies, directions and restrictions as the
Corporation shall from time to time establish. During the period of his
employment by the Corporation, Executive agrees to be bound by the Corporation’s
Code of Ethics and any amendments adopted thereto, copies of which Executive
hereby acknowledges he has received and read, and Executive agrees that he shall
not, without the prior written approval of the Board, directly or indirectly,
accept employment or compensation from or perform services of any nature for,
any business enterprise other than the Corporation, other than as explicitly set
forth herein.

3. Term. Executive shall be employed under this Agreement for a term commencing
on February 1, 2011 (the “Commencement Date”), and ending on the termination
date as provided in this Section 3 or as provided in Section 8 hereof. The term
of this Agreement shall automatically renew on the one-year anniversary date of
the Commencement Date of each year hereafter for successive one-year terms
unless either party delivers written notice of the termination of this Agreement
to the other party not more than 30 days before the expiration of the applicable
one-year period.

4. Compensation/Benefits.

4.1 The Corporation will pay to Executive as compensation for his services
hereunder an initial base salary of $175,000 per annum, payable in equal
biweekly installments. Provided that Executive continues to serve as the
Corporation’s Vice President – Product Development and Manufacturing for the
first one year of the term of this Agreement, the Corporation shall pay
Executive a cash bonus of up to $35,000 upon attainment within that one-year
period of the corporate goals set forth in the 2011 ImmunoCellular Corporate
Objectives (the “Corporate Goals”), which are subject to revision and
finalization by the Board within 90 days from the Commencement Date. The portion
of the $35,000 maximum bonus that shall be earned by Executive shall be
determined in the sole discretion of the Board and shall be based upon both
(i) the Board’s performance evaluation of Executive and (ii) with reference to
the formula set forth in the Corporate Goals and with the determination of
whether specified goals have been obtained to be made solely by the Board in its
good faith; provided that the bonus amount awarded by the Board may be greater
or lesser than the amount indicated by the goals formula. The Board shall
annually review Executive’s performance and base salary to determine whether an
increase in the amount thereof is warranted. Executive acknowledges that he has
been paid by the Corporation all amounts owing under the Prior Agreement.

4.2 The Corporation shall grant the Executive on the later of the date of the
Board’s approval of this Agreement or the execution of this Agreement by the
parties under the Corporation’s 2006 Equity Incentive Plan (the “Plan”), a stock
option (the “Option”) to purchase 120,000 shares of the Corporation’s common
stock (“Common Stock”) having an exercise price per share equal to the closing
market price on the date of grant and having a term of seven years from the date
of grant. The Option shall be an incentive stock option to the maximum extent
that is legally permitted. The Option shall vest (i) as to 60,000 shares in
three annual installments of 20,000 shares each, with the first installment to
vest on February 1, 2012; (ii) as to 20,000 shares upon the Corporation
attaining a market capitalization (defined for purposes of this Agreement as the
number of shares of the Corporation’s common stock then outstanding times the
average closing price of such common stock for ten consecutive trading days) of
at least $100 million; (iii) as to 20,000

 

2

--------------------------------------------------------------------------------

shares upon the Corporation attaining a market capitalization of at least $150
million; and (iv) as to 20,000 shares upon the Corporation attaining a market
capitalization of at least $200 million.

The Option will be exercisable within the seven year term of the option during
the period that Executive provides services to the Corporation and for twelve
months after termination for any reason except termination for cause by the
Corporation, provided that such exercise is effected within the seven-year term
of the Option. In the event of a Corporate Transaction (as such term is defined
in the Plan), vesting of the Option (and any other options granted to Executive)
shall be governed by the provisions contained in the Corporation’s standard
stock option agreement under the Plan for the Corporation’s officers and
directors, except that any then outstanding but unvested portion of the Option
will fully vest if the Corporation is not the surviving entity in the Corporate
Transaction unless the surviving entity offers Executive an executive position
at a compensation level at least equal to Executive’s then compensation level
under this Agreement. The Option will have such other terms and conditions as
are included in the Corporation’s standard stock option agreement under the
Plan. If the term of this Agreement continues beyond January 31, 2012, the Board
shall review the aggregate number of stock options granted to the Executive
promptly following such date (and thereafter not less frequently than annually)
in order to determine whether an increase in the number thereof is warranted.

5. Business Expenses. The Corporation will promptly reimburse Executive for all
business expenses incurred by Executive in connection with the business of the
Corporation in accordance with the Corporation’s policy regarding the nature and
amount of expenses and the maintenance and submission of receipts and records
necessary for the Corporation to document them as proper business expenses.

6. Vacation. In addition to holidays observed by the Corporation, Executive
shall be entitled to paid vacation of two weeks per year or such greater amount
of vacation as is approved by the Corporation’s President and Chief Executive
Officer. Any such vacations are to be taken at times mutually agreeable to
Executive and the Corporation’s President and Chief Executive Officer. Executive
shall not be entitled to accrue more than four weeks of accrued vacation time at
any given time. In the event that Executive has accrued the maximum of four
weeks accrued and unused vacation time, Executive shall cease accruing further
vacation time until such time as Executive’s accrued and unused vacation time is
less than such maximum amount.

7. Benefits. Executive shall be entitled to all rights and benefits for which he
shall be eligible under any benefit or other plans (including, without
limitation, dental, medical, medical reimbursement and hospital plans, pension
plans, employee stock purchase plans, profit sharing plans, bonus plans and
other so-called “fringe” benefits) as the Corporation shall make available to
its executive officers from time to time.

 

3

--------------------------------------------------------------------------------

8. Termination.

8.1 In addition to all other rights and remedies which the parties may have
under applicable law, the Corporation may terminate this Agreement and the
services of Executive, effective upon the occurrence of any of the following
events, any of which shall constitute a termination for “cause” under this
Agreement: (i) a failure by Executive to perform any of his material obligations
under this Agreement or to execute and perform in a timely and cooperative
manner any directions of the Corporation’s President and Chief Executive
Officer; (ii) the death of Executive or his disability resulting in his
inability to perform his reasonable duties assigned hereunder for a period of
three consecutive months; (iii) Executive’s theft, dishonesty, or falsification
of any Corporation documents or records; (iv) Executive’s improper use or
disclosure of the Corporation’s confidential or proprietary information; or
(v) Executive’s conviction (including any plea of guilty or nolo contendere) of
any criminal act which impairs Executive’s ability to perform his or her duties
hereunder or which in the Corporation’s judgment may materially damage the
business or reputation of the Corporation; provided, however, that prior to
termination for cause arising under clause (i), Executive shall have a period of
ten days after written notice from Corporation to cure the event or grounds
constituting such cause. Any notice of termination provided by Corporation to
Executive under this Section 8 shall identify the events or conduct constituting
the grounds for termination with sufficient specificity so as to enable
Executive to take steps to cure the same if such default is a failure by
Executive to perform any of his material obligations under this Agreement. In
the event Corporation terminates Executive for cause, (i) Executive shall be
entitled as of the termination date to no further base salary other than such
portion of Executive’s base salary as shall have accrued but remain unpaid as of
the termination date, which shall be due immediately upon termination,
(ii) Executive shall be entitled to receive payment of any earned but unpaid
bonus, as well as any expense reimbursement amounts owed by the Corporation to
the Executive through the date of termination and (iii) any then unexercised but
outstanding stock options granted to Executive shall be cancelled. The
Corporation shall have no further obligations to Executive under this Agreement.

8.2 The Corporation may terminate Executive without cause upon 60 days written
notice delivered to Executive. In the event the Corporation terminates
Executive’s employment without cause, all of the following will apply:
(i) immediately upon termination, the Corporation will pay to Executive any base
salary as shall have accrued but remain unpaid as of the termination date, any
earned but unpaid bonus and any expense reimbursement amounts owed by the
Corporation to the Executive through the date of termination; (ii) immediately
upon termination, the Corporation will pay to Executive severance compensation
in a lump sum cash payment equal to Executive’s then effective base salary for a
period of six (6) months; (iii) any stock options granted to Executive, to the
extent vested, will be retained by the Executive and will be exercisable as set
forth in Section 4.2 hereof, the Plan and related stock option agreement (which
shall reflect the terms set forth in Section 4.2 hereof); and (iv) the vesting
of an additional number of shares subject to those options granted to Executive
that vest solely based upon the passage of time equal to 50% of all such shares
subject to such time vesting based options that have not already vested shall
immediately accelerate and become fully vested and exercisable by Executive and
will continue to be exercisable as provided in Section 4.2 hereof, the Plan and
related stock option agreement (which shall reflect the terms set forth in
Section 4.2 hereof).

8.3 Executive may terminate Executive’s employment at will (without “Good
Reason” as defined below) by giving 60 days’ prior written notice to
Corporation. Executive shall be entitled to (i) all base salary up to and
through the 60-day period after

 

4

--------------------------------------------------------------------------------

Executive’s notice of termination is given to Corporation, any earned but unpaid
bonus and any expense reimbursement amounts owed by the Corporation to the
Executive through the date of termination and (ii) any stock options, to the
extent vested, may be retained by Executive and will be exercisable as set forth
in Section 4.2 hereof, the Plan and applicable stock option agreement (which
shall reflect the terms set forth in Section 4.2 hereof). Executive has the
right to terminate Executive’s employment for “Good Reason” due to, and not less
than 30 days following, the occurrence of any of the following:
(i) Corporation’s requirement that Executive’s principal place of work relocate
more than 50 miles from his principal place of work as of the Commencement Date
without the written consent of Executive to such relocation, (ii) a material
adverse change in Executive’s duties and responsibilities; (iii) any failure by
Corporation to pay, or any material reduction by Corporation of, the base salary
or any failure by Corporation to pay any incentive compensation to which
Executive is entitled pursuant to Section 4 hereof; or (iv) Corporation creates
a work environment designed to constructively terminate Executive or to
unlawfully harass or retaliate against Executive. In the event that Executive
terminates his employment for Good Reason, all of the following will apply:
(A) within five days after the termination date, Corporation will pay to
Executive any base salary as shall have accrued but remain unpaid as of the
termination date, any earned but unpaid bonus and any expense reimbursement
amounts owed by the Corporation to the Executive through the date of
termination; (B) within five days after the termination date, Corporation will
pay to Executive severance compensation in a lump sum cash payment equal to
Executive’s base salary then in effect equal to six (6) months (or an amount
equal to one year of the Executive’s then base salary if the Good Reason
Termination is in connection with a Corporate Transaction in which the
Corporation is not the surviving entity and the surviving entity fails to offer
Executive an executive position at a compensation level at least equal to the
Executive’s then compensation level under this Agreement); (C) any stock options
granted to Executive, to the extent vested, will be retained by the Executive
and will be exercisable as set forth in Section 4.2 hereof, the Plan and related
stock option agreement (which shall reflect the terms set forth in Section 4.2
hereof); and (D) the vesting of an additional number of shares subject to all
options granted to Executive that vest solely based upon the passage of time
equal to 50% of all such shares (or 100% of all such time vesting based option
shares as well as all then outstanding unvested milestone based option shares
shall vest if the Good Reason termination is in connection with a Corporate
Transaction in which the Corporation is not the surviving entity and the
surviving entity fails to offer Executive an executive position at a
compensation level at least equal to Executive’s then compensation level under
this Agreement) subject to such time vesting based options that have not already
vested shall immediately accelerate and become fully vested and exercisable by
Executive and will continue to be exercisable as provided in Section 4.2 hereof,
the Plan and related stock option agreement (which shall reflect the terms set
forth in Section 4.2 hereof).

9. Indemnity. Executive warrants and represents that he has full power and
authority to enter into and perform this Agreement and that his performance of
this Agreement will not violate the provisions of any other agreement to which
he is a party. The Corporation agrees to indemnify and hold Executive harmless
from and against any and all claims, demands, causes of action, losses, damages,
liability, costs and expenses, including attorneys fees arising out of his
services hereunder, other than those arising from or attributable to or
resulting from his gross negligence or willful misconduct. The Corporation will
name Executive as an officer on any policy of directors and officers liability
insurance it secures throughout the term of this Agreement.

 

5

--------------------------------------------------------------------------------

10. Non-Competition. In consideration of the Corporation’s entering into this
Agreement:

10.1 Executive agrees that during the term of this Agreement he will not
directly or indirectly own, manage, operate, join, control, participate in,
perform any services for, invest in, or otherwise be connected with, in any
manner, whether as an officer, director, employee, consultant, partner, investor
or otherwise, any business entity which is engaged in any business in which the
Corporation is currently engaged or is engaged at the termination of this
Agreement without an approval from the Corporation. Nothing herein contained
shall be deemed to prohibit (i) Executive from maintaining any investments in,
and the holding of any securities of, any company to the extent such investments
were made or such securities held by Executive prior to the Commencement Date or
(ii) investing his funds in securities of a company if the securities of such
company are listed for trading on a national securities exchange or traded in
the over the counter market and Executive’s holdings therein represent less than
5% of the total number of shares or principal amount of other securities of such
company outstanding.

10.2 Executive agrees that Executive will not, during the term hereof or prior
to the expiration of one year following the termination of the Executive’s
employment for any reason, without the written consent of the Corporation,
directly or indirectly, by action alone or in concert with others, solicit for
employment or engagement, or advise or recommend to any other person or entity
that such person or entity solicit for employment or engagement, any person or
entity employed or engaged by the Corporation.

11. Confidentiality Agreement.

11.1 As used herein, the term “Confidential Information” shall mean the any and
all information of the Corporation, including, but not limited to, all data,
compilations, programs, devices, strategies, or methods concerning or related to
(i) the Corporation’s finances, financial condition, results of operations,
employee relations, amounts of compensation paid to officers and employees and
any other data or information relating to the internal affairs of the
Corporation and its operations; (ii) the terms and conditions (including prices)
of sales and offers of sales of the Corporation’s products and services;
(iii) the terms, conditions and current status of the Corporation’s agreements
and relationship with any customer or supplier; (iv) the customer and supplier
lists and the identities and business preferences of the Corporation’s actual
and prospective customers and suppliers or any employee or agent thereof with
whom the Corporation communicates; (v) the trade secrets, manufacturing and
operating techniques, price data, costs, methods, systems, plans, procedures,
formulas, processes, hardware, software, machines, inventions, designs,
drawings, artwork, blueprints, specifications, tools, skills, ideas, and
strategic plans possessed, developed, accumulated or acquired by the
Corporation; (vi) any communications between the Corporation, its officers,
directors, shareholders, or employees, and any attorney retained by the
Corporation for any purpose, or any person retained or employed by such attorney
for the purpose of assisting such attorney in his or her representation of the
Corporation; (vii) any

 

6

--------------------------------------------------------------------------------

other non-public information and knowledge with respect to the Corporation’s
products, whether developed or in any stage of development by the Corporation;
(viii) the abilities and specialized training or experience of others who as
employees or consultants of the Corporation during the Executive’s employment
have engaged in the design or development of any such products; and (ix) any
other matter or thing, whether or not recorded on any medium, (a) by which the
Corporation derives actual or potential economic value from such matter or thing
being not generally known to other persons or entities who might obtain economic
value from its disclosure or use, or (b) which gives the Corporation an
opportunity to obtain an advantage over its competitors who do not know or use
the same.

11.2 Executive acknowledges and agrees that the Corporation is engaged in a
highly competitive business and has expended, or will expend, significant sums
of money and has invested, or will invest, a substantial amount of time to
develop and maintain the secrecy of the Confidential Information. The
Corporation has thus obtained, or will obtain, a valuable economic asset which
has enabled, or will enable, it to develop an extensive reputation and to
establish long-term business relationships with its suppliers and customers. If
such Confidential Information were disclosed to another person or entity or used
for the benefit of anyone other than the Corporation, the Corporation would
suffer irreparable harm, loss and damage. Accordingly, Executive acknowledges
and agrees that, unless the Confidential Information was (a) in the public
domain or becomes publicly known through legitimate origins not involving an act
or omission by Executive, (b) was in Executive’s possession free of any
obligation of confidence at or subsequent to the time such Confidential
Information was communicated to Executive; (c) was developed by Executive prior
to the date of this Agreement or after the expiration of the term of this
Agreement independently of and without reference to any Confidential
Information; (c) was known to Executive at the time of disclosure; or (v) was
approved for release by written authorization of the Corporation, then:

(i) the Confidential Information is, and at all times hereafter shall remain,
the sole property of the Corporation;

(ii) Executive shall use his best efforts and the utmost diligence to guard and
protect the Confidential Information from disclosure to any competitor, customer
or supplier of the Corporation or any other person, firm, corporation or other
entity; and

(iii) unless the Corporation gives Executive prior express written permission,
during his employment and thereafter, Executive shall not use for his own
benefit, or divulge to any competitor or customer or any other person, firm,
corporation, or other entity, any of the Confidential Information which
Executive may obtain, learn about, develop or be entrusted with as a result of
Executive’s employment by the Corporation.

11.3 Executive also acknowledges and agrees that all documentary and tangible
Confidential Information including, without limitation, such Confidential
Information as Executive has committed to memory, is supplied or made available
by the Corporation to the Executive solely to assist him in performing his
services under this Agreement. Executive further agrees that after his
employment with the Corporation is terminated for any reason:

 

7

--------------------------------------------------------------------------------

(i) Executive shall not remove from the property of the Corporation and shall
immediately return to the Corporation, all documentary or tangible Confidential
Information in his possession, custody, or control and not make or keep any
copies, notes, abstracts, summaries or other record of any type of Confidential
Information; and

(ii) Executive shall immediately return to the Corporation any and all other
property of the Corporation in his possession, custody or control, including,
without limitation, any and all keys, security cards, passes, credit cards and
marketing literature.

12. Invention Disclosure. Executive agrees to disclose to the Corporation
promptly and fully all ideas, inventions, discoveries, developments or
improvements (“Inventions”) that may be made, conceived, created or developed by
him (whether such Inventions are developed solely by him or jointly with others)
during his employment by the Corporation which either (i) in any way is
connected with or related to the actual or contemplated business, work, research
or undertakings of the Corporation or (ii) results from or is suggested by any
task, project or work that he may do for, in connection with, or on behalf of
the Corporation. Notwithstanding the foregoing, this Section 12 shall not apply
to any Inventions that meet all of the following requirements: (a) do not
relate, at the time of conception, reduction to practice, creation, derivation,
development or making of such Invention to the Corporation’s business or actual
or demonstrably anticipated research, development or business; and (b) were
developed entirely on Executive’s own time; and (c) were developed without use
of any of the Corporation’s equipment, supplies, facilities or trade secret
information; and (d) did not result from any work Executive performed for the
Corporation. Executive agrees that such Inventions shall become the sole and
exclusive property of the Corporation and Executive hereby assigns to the
Corporation all of his rights to any such Inventions. With respect to
Inventions, Executive shall during the period of his employment hereunder and at
any time and from time to time hereafter (a) execute all documents requested by
the Corporation for vesting in the Corporation the entire right, title and
interest in and to the same, (b) execute all documents requested by the
Corporation for filing and prosecuting such applications for patents, trademarks
and/or copyrights as the Corporation, in its sole discretion, may desire to
prosecute, and (c) give the Corporation all assistance it reasonably requires,
including the giving of testimony in any suit, action or proceeding, in order to
obtain, maintain and protect the Corporation’s right therein and thereto. If any
such assistance is required following the termination of Executive’s employment
with the Corporation, the Corporation shall reimburse Executive for his lost
wages or salary and the reasonable expenses incurred by him in rendering such
assistance.

13. Remedies. Executive acknowledges and agrees that the business of the
Corporation is highly competitive and that the provisions of Sections 10, 11 and
12 are reasonable and necessary for the protection of the Corporation and that
any violation of such covenants would cause immediate, immeasurable and
irreparable harm, loss and damage to the Corporation not adequately compensable
by a monetary award. Accordingly, the Executive agrees, without limiting any of
the other remedies available to the Corporation, that any violation of said
covenants, or any one of them, may be enjoined or restrained by any court of
competent jurisdiction, and that any temporary restraining order or emergency,
preliminary or final injunctions may be issued by any court of competent
jurisdiction, without notice and without bond.

 

8

--------------------------------------------------------------------------------

14. Attorneys’ Fees and Costs. In any action between the parties based on this
Agreement, the prevailing party shall be entitled to recovery of reasonable
attorneys’ fees and out-of-pocket costs incurred by such party in the action.

15. Entire Agreement. This Agreement constitutes the entire agreement of the
parties hereto with respect to the matters set forth herein and no amendment or
modification hereof shall be valid or binding unless made in writing and signed
by both parties hereto.

16. Notices. Any notice, required, permitted or desired to be given pursuant to
any of the provisions of this Agreement shall be deemed to have been
sufficiently given or served for all purposes if delivered in person or sent by
certified mail, return receipt requested, postage and fees prepaid as follows:

 

if to the Corporation, at:

 

ImmunoCellular Therapeutics, Ltd.

21900 Burbank Boulevard, 3rd Floor

Woodland Hills, CA 91367

Attention: Chairman of the Board

 

with a copy to:

 

TroyGould PC

1801 Century Park East, Suite 1600

Los Angeles, California 90067

Attention: Sanford J. Hillsberg

 

and, if to Executive:

 

Dr. Manish Singh

23526 Dolorosa Street

Woodland Hills, California 91367

Either of the parties hereto may at any time and from time to time change the
address to which notice shall be sent hereunder by notice to the other party
given as provided herein. The date of the giving of any notice hereunder shall
be the date delivered or if sent by mail, shall be the date of the posting of
the mail.

17. Non Assignability. Neither this Agreement nor the right to receive any
payments hereunder may be assigned by Executive. This Agreement shall be binding
upon Executive and inure to the benefit of his heirs, executors and
administrators and be binding upon the Corporation and inure to the benefit of
its successors and assigns.

 

9

--------------------------------------------------------------------------------

18. Choice of Law And Forum. This Agreement shall be governed, interpreted and
construed under the laws of the State of California without regard to its
conflict of law principles. In the event of any dispute under this Agreement,
such dispute shall be resolved by binding arbitration with JAMS/ENDISPUTE in Los
Angeles, California. The arbitrator shall be a retired judge with at least five
years of experience on the bench. This provision shall not be interpreted so as
to require arbitration of claims that the state and/or Federal courts of
California have ruled may not be the subjects of compelled arbitration in
employment matters, nor shall it be interpreted so as to restrict any remedy,
right of appeal or discovery device available to either party in a manner that
violates the rulings of the state and/or Federal courts of California with
respect to employment-related arbitration. This provision shall not be
interpreted so as to preclude the making of reports to governmental offices, or
to preclude either party from seeking injunctive or provisional relief in a
court of appropriate jurisdiction under such circumstances as may merit such
relief.

19. Waiver. No course of dealing nor any delay on the part of any party in
exercising any rights hereunder shall operate as a waiver of any such rights. No
waiver of any default or breach of this Agreement shall be deemed a continuing
waiver or a waiver of any other breach or default.

20. Severability. If any provision of this Agreement, including any paragraph,
sentence, clause or part thereof, shall be deemed contrary to law or invalid or
unenforceable in any respect by a court of competent jurisdiction, the remaining
provisions of such paragraph, sentence, clause or part thereof shall not be
affected, but shall, subject to the discretion of such court, remain in full
force and effect and any invalid and unenforceable provisions shall be deemed,
without further action on the part of the parties hereto, modified, amended and
limited to the extent necessary to render the same valid and enforceable.

21. Section 409A. If Executive becomes eligible for payments under this
Agreement on account of his “separation from service,” within the meaning of
Section 409A of the Internal Revenue Code of 1986, as amended, (the “Code”) and
Executive is a “specified employee” within the meaning of Section 409A of the
Code, as determined by Corporation, any portion of the payments that either do
not qualify under the “short-term deferral rule” or exceed two times the lesser
of (A) Executive’s “annualized compensation” for the calendar year preceding
Executive’s separation from service (in each case, as those terms are defined
under Section 409A of the Code), or (B) the maximum amount that may be taken
into account under Section 401(a)(17) of the Code for the year in which
Executive’s separation from service occurs, and which are not otherwise exempt
from Section 409A of the Code, shall be accrued, without interest, and its
payment delayed until the first day of the seventh month following Executive’s
separation from service, or if earlier, Executive’s death, at which point the
accrued amount will be paid in a single, lump sum cash payment. Furthermore,
Corporation shall not be required to make, and Executive shall not be required
to receive, any severance or other payment or benefit under this Agreement at
such time as the making of such payment or the provision of such benefit or the
receipt thereof shall result in a tax to Executive arising under Section 409A of
the Code. The preceding provisions, however, shall not be construed as a
guarantee by the Corporation of any particular tax effect to Executive under
this Agreement. The parties agree that for purposes of Section 409A of the Code,
the severance amounts payable under this Agreement shall be treated as a right
to a series of

 

10

--------------------------------------------------------------------------------

separate payments. This Agreement is intended to comply with, or otherwise be
exempt from, Section 409A of the Code. This Agreement shall be administered,
interpreted and construed in a manner consistent with Section 409A of the Code.
The Corporation and Executive agree that they will execute any and all
amendments to this Agreement as they mutually agree in good faith may be
necessary to ensure compliance with the provisions of Section 409A of the Code.

22. Survival at Termination. The termination of Executive’s employment hereunder
by expiration of the term of this Agreement or otherwise shall not affect his
obligations to the Corporation hereunder which by the nature thereof are
intended to survive any such termination including, without limitation,
Executive’s obligations under Sections 10, 11, 12, 13 and 21 hereof.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed as of the date first above set forth.

 

IMMUNOCELLULAR THERAPEUTICS, LTD.       EXECUTIVE: By:   

/s/ Manish Singh

     

/s/ James Bender

   Manish Singh, Ph.D.       James Bender, Ph.D. Its:    President and Chief
Executive Officer      

 

11